keyword
MENU ▼
Read by QxMD icon Read
search

NCCN

keyword
https://www.readbyqxmd.com/read/29221719/integration-of-different-criteria-for-borderline-resectable-pancreatic-cancer-using-classification-tree-analysis-the-use-of-radiological-tumour-vascular-interface-in-correlation-with-surgical-and-pathological-outcomes
#1
J A Hwang, K M Jang, S H Kim, T W Kang, K D Song, D I Cha, S Ahn
AIM: To integrate various criteria for borderline resectable pancreatic cancer (BRPC) based on radiological parameters using classification tree analysis. MATERIALS AND METHODS: The institutional review board approved this retrospective study and waived the requirement for informed consent. Two hundred and thirty-five tumour-vein interfaces and 67 tumour-artery interfaces in 245 patients with surgically confirmed pancreatic ductal adenocarcinoma who underwent both preoperative computed tomography (CT) and magnetic resonance imaging (MRI) were assessed by two independent readers...
December 5, 2017: Clinical Radiology
https://www.readbyqxmd.com/read/29221286/automatic-lung-rads%C3%A2-classification-with-a-natural-language-processing-system
#2
Sebastian E Beyer, Brady J McKee, Shawn M Regis, Andrea B McKee, Sebastian Flacke, Gilan El Saadawi, Christoph Wald
Background: Our aim was to train a natural language processing (NLP) algorithm to capture imaging characteristics of lung nodules reported in a structured CT report and suggest the applicable Lung-RADS™ (LR) category. Methods: Our study included structured, clinical reports of consecutive CT lung screening (CTLS) exams performed from 08/2014 to 08/2015 at an ACR accredited Lung Cancer Screening Center. All patients screened were at high-risk for lung cancer according to the NCCN Guidelines®...
September 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29206324/ahns-series-do-you-know-your-guidelines-evidence-based-management-of-oral-cavity-cancers
#3
Amarbir Gill, Nilesh Vasan, Babak Givi, Arjun Joshi
Oral cavity squamous cell carcinoma (OCSCC) is the most common nonmelanoma head and neck cancer in the world, with an estimated 405 000 new cases expected each year. Subsites of the oral cavity include the alveolar ridge, buccal mucosa, anterior tongue, tonsillar pillar, retromolar trigone, hard palate, gingiva, and floor of the mouth. In this issue of the AHNS "Do you know your guidelines?" series, we review the evidence-based approach to the management of oral cavity carcinomas based on the framework provided by the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology...
December 5, 2017: Head & Neck
https://www.readbyqxmd.com/read/29203992/molecular-landscape-and-treatment-options-for-patients-with-metastatic-colorectal-cancer
#4
REVIEW
Yuji Miyamoto, Wu Zhang, Heinz-Josef Lenz
Over the last 20 years, median survival for patients with metastatic colorectal cancer (CRC) has remarkably improved from about 12 to over 30 months, mainly because of the development of new agents and patient selection using predictive biomarkers. However, the identification of the most effective treatment for an individual patient is still a challenge. Molecular profiling of CRC has made great progress, but it is limited by tumor heterogeneity and absence of driver mutation. However, RAS, BRAF, and microsatellite instability are validated biomarker recommended by NCCN and ESMO...
December 2017: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29200417/new-guidelines-from-the-nccn-for-polycythemia-vera
#5
Ruben A Mesa
No abstract text is available yet for this article.
November 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29191513/international-consensus-on-definition-and-criteria-of-borderline-resectable-pancreatic-ductal-adenocarcinoma-2017
#6
Shuji Isaji, Shugo Mizuno, John A Windsor, Claudio Bassi, Carlos Fernández-Del Castillo, Thilo Hackert, Aoi Hayasaki, Matthew H G Katz, Sun-Whe Kim, Masashi Kishiwada, Hirohisa Kitagawa, Christoph W Michalski, Christopher L Wolfgang
This statement was developed to promote international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) which was adopted by the National Comprehensive Cancer Network (NCCN) in 2006, but which has changed yearly and become more complicated. Based on a symposium held during the 20th meeting of the International Association of Pancreatology (IAP) in Sendai, Japan, in 2016, the presenters sought consensus on issues related to BR-PDAC. We defined patients with BR-PDAC according to the three distinct dimensions: anatomical (A), biological (B), and conditional (C)...
November 22, 2017: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
https://www.readbyqxmd.com/read/29190915/the-prognostic-significance-of-cd11b-cx3cr1-monocytes-in-patients-with-newly-diagnosed-diffuse-large-b-cell-lymphoma
#7
Ho-Young Yhim, Jeong-A Kim, Sun-Hye Ko, Youngrok Park, Eunjung Yim, Hee Sun Kim, Jae-Yong Kwak
Despite their critical roles in angiogenesis and host immunosuppression within the tumor microenvironment, the prognostic significance of myeloid-lineage cells expressing CD11b and CX3CR1 in diffuse large B-cell lymphoma (DLBCL) has not been well studied. We prospectively enrolled newly-diagnosed DLBCL patients at two Korean institutions between May 2011 and Aug 2015. CD11b+CX3CR1+ cells were analyzed by flow cytometry using peripheral blood (PB) and bone marrow (BM) aspirate samples before treatments. Eighty-nine patients (52 males) were enrolled...
November 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29190906/improved-prognostic-stratification-using-nccn-and-geltamo-international-prognostic-index-in-patients-with-diffuse-large-b-cell-lymphoma
#8
Junshik Hong, Seok Jin Kim, Myung Hee Chang, Jeong-A Kim, Jae-Yong Kwak, Jin Seok Kim, Dok Hyun Yoon, Won Sik Lee, Young Rok Do, Hye Jin Kang, Hyeon-Seok Eom, Yong Park, Jong-Ho Won, Yeung-Chul Mun, Hyo Jung Kim, Jung Hye Kwon, Jee Hyun Kong, Sung Yong Oh, Sunah Lee, Sung Hwa Bae, Deok-Hwan Yang, Hyun Jung Jun, Ho Sup Lee, Hwan Jung Yun, Soon Il Lee, Min Kyoung Kim, Jun Ho Yi, Jae Hoon Lee, Won Seog Kim, Cheolwon Suh
The National Comprehensive Cancer Network (NCCN)-International Prognostic Index (IPI) and GELTAMO (Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea)-IPI were developed to enable better risk prediction of patients with diffuse large B-cell lymphoma (DLBCL). The present study compared the effectiveness of risk prediction between IPI, NCCN-IPI, and GELTAMO-IPI in patients with DLBCL particularly in terms of determining high-risk patients. Among 439 patients who were enrolled to a prospective DLBCL cohort treated with R-CHOP immunochemotherapy, risk groups were classified according to the three IPIs and the prognostic significance of individual IPI factors and IPI models were analyzed and compared...
November 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29185869/development-and-validation-of-a-novel-integrated-clinical-genomic-risk-group-classification-for-localized-prostate-cancer
#9
Daniel E Spratt, Jingbin Zhang, María Santiago-Jiménez, Robert T Dess, John W Davis, Robert B Den, Adam P Dicker, Christopher J Kane, Alan Pollack, Radka Stoyanova, Firas Abdollah, Ashley E Ross, Adam Cole, Edward Uchio, Josh M Randall, Hao Nguyen, Shuang G Zhao, Rohit Mehra, Andrew G Glass, Lucia L C Lam, Jijumon Chelliserry, Marguerite du Plessis, Voleak Choeurng, Maria Aranes, Tyler Kolisnik, Jennifer Margrave, Jason Alter, Jennifer Jordan, Christine Buerki, Kasra Yousefi, Zaid Haddad, Elai Davicioni, Edouard J Trabulsi, Stacy Loeb, Ashutosh Tewari, Peter R Carroll, Sheila Weinmann, Edward M Schaeffer, Eric A Klein, R Jeffrey Karnes, Felix Y Feng, Paul L Nguyen
Purpose It is clinically challenging to integrate genomic-classifier results that report a numeric risk of recurrence into treatment recommendations for localized prostate cancer, which are founded in the framework of risk groups. We aimed to develop a novel clinical-genomic risk grouping system that can readily be incorporated into treatment guidelines for localized prostate cancer. Materials and Methods Two multicenter cohorts (n = 991) were used for training and validation of the clinical-genomic risk groups, and two additional cohorts (n = 5,937) were used for reclassification analyses...
November 29, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29180936/osimertinib-effective-treatment-of-nsclc-with-activating-egfr-mutations-after-progression-on-egfr-tyrosine-kinase-inhibitors
#10
Marcin Skrzypski, Amelia Szymanowska-Narloch, Rafał Dziadziuszko
Non-small cell lung cancer (NSCLC) driven by activating mutations in epidermal growth factor receptor (EGFR) constitutes up to 10% of NSCLC cases. According to the NCCN recommendations, all patients (with the exception of smoking patients with squamous cell lung cancer) should be screened for the presence of activating EGFR mutations, i.e. deletion in exon 19 or point mutation L858R in exon 21, in order to select the group that benefits from EGFR tyrosine kinase inhibitors (EGFR TKIs) treatment. Among approved agents there are the 1st generation reversible EGFR TKIs, erlotinib and gefitinib, and the 2nd generation irreversible EGFR TKI, afatinib...
2017: Contemporary Oncology Współczesna Onkologia
https://www.readbyqxmd.com/read/29178322/literacy-analysis-of-national-comprehensive-cancer-network-patient-guidelines-for-the-most-common-malignancies-in-the-united-states
#11
Bao Ngoc N Tran, Qing Z Ruan, Sherise Epstein, Joseph A Ricci, Rima E Rudd, Bernard T Lee
BACKGROUND: Cancer information is of critical interest to the public. The National Comprehensive Cancer Network (NCCN) offers a series of comprehensive patient guidelines on the management of the most common cancer diagnoses. This study was aimed at assessing the health literacy demands of NCCN patient guidelines for the most common malignancies in the United States. METHODS: The American Cancer Society's most common malignancies by annual incidence in the United States and their corresponding NCCN patient guidelines were identified...
November 27, 2017: Cancer
https://www.readbyqxmd.com/read/29172293/oncologists%C3%A2-perspectives-on-consolidation-radiation-treatment-after-chemotherapy-for-lymphomas-a-survey-study-by-the-lymphoma-working-committee-of-the-turkish-oncology-group-tog
#12
Ozgur Tanriverdi, Ibrahim Barista, Semra Paydas, Erdinc Nayir, Yusuf Karakas
In this study, we aimed to determine the perspectives of medical and radiation oncologists regarding consolidation radiotherapy in patients with a complete response after chemotherapy for Hodgkin’s and non-Hodgkin’s lymphomas. The survey was designed to identify demographic and occupational features of medical and radiation oncologists and their views on application of consolidation radiotherapy in their clinical practices, as based on a five-point Likert scale (never, rarely, sometimes, often, and always)...
November 26, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/29164420/brcasearch-written-pre-test-information-and-brca1-2-germline-mutation-testing-in-unselected-patients-with-newly-diagnosed-breast-cancer
#13
Martin P Nilsson, Therese Törngren, Karin Henriksson, Ulf Kristoffersson, Anders Kvist, Barbro Silfverberg, Åke Borg, Niklas Loman
PURPOSE: To evaluate a simplified method of pre-test information and germline BRCA1/2 mutation testing. METHODS: In a prospective, single-arm study, comprehensive BRCA1/2 testing was offered to unselected patients with newly diagnosed breast cancer at three hospitals in south Sweden (BRCAsearch, ClinicalTrials.gov Identifier: NCT02557776). Pre-test information was provided by a standardized invitation letter, but the patients could contact a genetic counselor for telephone genetic counseling if they felt a need for that...
November 21, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29161300/brca1-and-brca2-mutational-profile-and-prevalence-in-hereditary-breast-and-ovarian-cancer-hboc-probands-from-southern-brazil-are-international-testing-criteria-appropriate-for-this-specific-population
#14
Bárbara Alemar, Cleandra Gregório, Josef Herzog, Camila Matzenbacher Bittar, Cristina Brinckmann Oliveira Netto, Osvaldo Artigalas, Ida Vanessa D Schwartz, Jordy Coffa, Suzi Alves Camey, Jeffrey Weitzel, Patricia Ashton-Prolla
BACKGROUND: Germline pathogenic variants in BRCA1 and BRCA2 (BRCA) are the main cause of Hereditary Breast and Ovarian Cancer syndrome (HBOC). METHODS: In this study we evaluated the mutational profile and prevalence of BRCA pathogenic/likely pathogenic variants among probands fulfilling the NCCN HBOC testing criteria. We characterized the clinical profile of these individuals and explored the performance of international testing criteria. RESULTS: A pathogenic/likely pathogenic variant was detected in 19...
2017: PloS One
https://www.readbyqxmd.com/read/29159978/ahns-series-do-you-know-your-guidelines-guideline-recommendations-for-head-and-neck-cancer-of-unknown-primary-site
#15
Antoine Eskander, Tamer Ghanem, Amit Agrawal
This article reviews the clinical practice guidelines for head and neck oncology focusing on the management of head and neck cancers of unknown primary (CUP). The primary purpose of this series is to raise awareness of the current guidelines in head and neck oncology by reviewing the recommendations and the evidence supporting such recommendations, particularly those published by the National Comprehensive Cancer Network (NCCN). We review the importance of a thorough history and physical examination, the impact of the American Joint Committee on Cancer (AJCC) eighth edition changes and the importance of immunohistochemistry, the timing and type of imaging, the role of panendoscopy and tonsillectomy (palatine and lingual), and the role of surgery, radiation, and chemotherapy in the primary management of these tumors...
November 21, 2017: Head & Neck
https://www.readbyqxmd.com/read/29156896/proutine-a-feasibility-study-assessing-surveillance-of-electronic-patient-reported-outcomes-and-adherence-via-smartphone-app-in-advanced-cancer
#16
Gesine Benze, Friedemann Nauck, Bernd Alt-Epping, Giuseppe Gianni, Thomas Bauknecht, Johannes Ettl, Anna Munte, Luisa Kretzschmar, Jan Gaertner
BACKGROUND: In advanced cancer, quality of life (QoL) is a major treatment goal. In order to achieve this, the identification of suffering by screening for patient-reported-outcomes (PROs, i.e., symptoms) is of utmost importance. The use of paper-pencil questionnaires is associated with significant shortcomings due to missing data, recall bias and transcription errors. Other than that, the electronic recording of PROs by mobile Health (mHealth) offers a number of advantages. The aim of this study was to test whether the routine assessment of PROs via a newly developed smartphone application (MeQoL®) is feasible...
October 26, 2017: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/29152166/a-retrospective-cohort-study-of-treatment-patterns-among-patients-with-metastatic-soft-tissue-sarcoma-in-the-us
#17
Victor M Villalobos, Stacey DaCosta Byfield, Sameer R Ghate, Oluwakayode Adejoro
Background: Since treatment patterns in metastatic soft tissue sarcoma (mSTS) have not been studied subsequent to US approval of pazopanib in 2012, this study sought to examine mSTS treatment patterns by line of therapy, including regimen and duration of therapy. Methods: This retrospective study employed administrative claims from a large US health plan from 1/2006-9/2015. Adult mSTS patients were required to have an NCCN-recommended therapy and be continuously enrolled in the health plan during the study period...
2017: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/29151174/the-impact-of-remission-status-on-patients-experiences-with-acute-myeloid-leukemia-aml-an-exploratory-analysis-of-longitudinal-patient-reported-outcomes-data
#18
Neha Kayastha, Steven P Wolf, Susan C Locke, Gregory P Samsa, Areej El-Jawahri, Thomas W LeBlanc
PURPOSE: Shared decision-making in acute myeloid leukemia (AML) requires understanding patients' longitudinal experiences of illness, but little is known about the impact of remission status on patient-reported outcomes (PROs). We aimed to explore the association between remission status and PROs 6-12 months following induction chemotherapy. METHODS: Forty-two patients completed three validated instruments characterizing symptom burden (Patient Care Monitor v2...
November 18, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29145591/asia-consensus-statement-on-nccn-clinical-practice-guideline-for-bladder-cancer
#19
Hiroyuki Nishiyama
The Asia Consensus Statement (ACS) on the NCCN Guideline (NCCN-ACS) for treatment of bladder cancer version 1.2016 is designed to provide documentation of modifications of the 'parent' NCCN Guideline: Bladder Cancer (Version 2.2015). When considering ethnic differences or differences in health regulatory environments between Western and Asian countries, a process of adaptation to match the circumstances is helpful for utilizing the guidelines. The NCCN-ACS for bladder cancer consist of 11 ACSs, focused on diagnosis, imaging, surgical treatment, adjuvant intravesical chemotherapy or immunotherapy, periopererative (neodjuvant or adjuvant) chemotherapy and radiation oncology including bladder preservation...
November 14, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29144866/challenges-in-the-clinical-application-of-the-american-society-of-clinical-oncology-value-framework-a-medicare-cost-benefit-analysis-in-chronic-lymphocytic-leukemia
#20
Erlene K Seymour, Charles A Schiffer, Jonas A de Souza
PURPOSE: The ASCO Value Framework calculates the value of cancer therapies. Given costly novel therapeutics for chronic lymphocytic leukemia, we used the framework to compare net health benefit (NHB) and cost within Medicare of all regimens listed in the National Comprehensive Cancer Network (NCCN) guidelines. METHODS: The current NCCN guidelines for chronic lymphocytic leukemia were reviewed. All referenced studies were screened, and only randomized controlled prospective trials were included...
November 16, 2017: Journal of Oncology Practice
keyword
keyword
30821
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"